Eli Lilly sues medical spas, clinics, and compounding pharmacies for selling counterfeit tirzepatide products Mounjaro and Zepbound.

Eli Lilly identifies bacteria and impurities in falsely labeled tirzepatide products in Mounjaro and Zepbound. The company is suing medical spas, weight-loss clinics, and compounding pharmacies to halt the sale of the counterfeit drugs, as it does not supply tirzepatide to compounding pharmacies. Fake versions pose serious health risks, and similar issues have affected Novo Nordisk's Ozempic.